Montréal — 14 décembre 2021 — Le CQDM se réjouit de l’annonce faite lundi dernier par Pierre Fitzgibbon, ministre de l’Économie et de l’Innovation et ministre responsable du Développement économique régional, dans le cadre du Forum stratégique sur l’industrie pharmaceutique de la Chambre de commerce du Montréal métropolitain. En effet, via le FACS, le Gouvernement du Québec financera à hauteur de … Read More
CQDM funds a project to improve the screening of lung cancer with BioMark Diagnostic Solutions, in partnership with AstraZeneca, Pfizer Canada and the IUCPQ Foundation
MONTREAL, November 30, 2021 – During this Lung Cancer Awareness Month, CQDM is proud to announce that it will co-fund a project driven by Dr Philippe Joubert and Pr. Yohan Bossé at the Quebec Heart and Lung Institute (Institut Universitaire de Cardiologie et Pneumologie du Québec-Université Laval – IUCPQ-UL) targeting a program of early-stage detection of lung cancer. Funding for … Read More
ADRIQ* 2021 AWARD – CQDM congratulates Feldan Therapeutics for receiving the 2021 ADRIQ RSRI (regroupements sectoriels de recherche industrielle) award.
MONTREAL, November 25, 2021 – The 2021 ADRIQ biopharmaceutical sector RSRI award was presented to Feldan Therapeutics, a Quebec City-based company that CQDM has been funding since 2018 as part of a collaborative research project. This project brought together a group of five major pharmaceutical companies, the Quebec biotech Feldan and academic institutions to validate and advance the Feldan Shuttle, … Read More
2021 Sweet Pharma Day Winner is HDAX Therapeutics
Montréal, Canada – (BUSINESSWIRE) October 8, 2021 – AmorChem, BioQuébec and CQDM, co-organizers of Sweet Pharma Day, are pleased to announce that HDAX Therapeutics is the winner of the 2021 edition. Sixteen Canadian startup companies (“Sweet 16”) selected by representatives from global pharma companies, made an elevator pitch in front of 150+ participants, who voted for HDAX Therapeutics as the … Read More
A new partnership between CQDM, the Canadian Cancer Society, the Cole Foundation and Oncopole to support pediatric cancer research
Montreal – October 7, 2021 – CQDM, the Canadian Cancer Society (CCS), the Cole Foundation (CF) and Oncopole – Pôle cancer du FRQS launch a first call for proposals to support collaborative R&D projects focusing on pediatric and young adult cancers, in particular leukemia and lymphoma. This new research funding, worth up to $5M, builds on CCS, CF, Oncopole and … Read More
CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies
CQDM invests in Montreal-based regenerative medicine company, Morphocell Technologies, to support the development of innovative therapies for acute liver failure Montréal – Québec – July 7 – CQDM is proud to announce an investment of $260,100 in Morphocell Technologies, a Montréal- based early-stage regenerative medicine company focused on the development of stem cell-derived engineered liver tissue to treat liver disease. … Read More
CQDM invests $500,000 in Giiant Pharma, a Quebec-based pharmaceutical company with strong potential in gastroenterology
Montreal – June 30th 2021 – CQDM is proud to invest in Giiant Pharma’s seed financing round, joining co-leads Amplitude Ventures and Genesys Capital, along with Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, AQC Capital, Anges Québec, and other angel investor. This financing will enable Giiant Pharma to become a leader in targeted drug delivery technologies to … Read More
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University
CQDM to fund an international collaboration between Raya Therapeutic, Eikonizo Therapeutics and McGill University to develop new treatments for Amyotrophic Lateral Sclerosis (ALS) MONTREAL, June 21, 2021 – On this Global Amyotrophic Lateral Sclerosis (ALS) Awareness Day, CQDM is proud to announce a new $1.7M international collaboration between McGill University, Raya Therapeutic (Montreal – Quebec) and Eikonizo Therapeutics (Cambridge – … Read More
CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet
CQDM sets up a collaboration between Simon Fraser University, Amgen, Merck, Servier and GlycoNet to develop new chemistry to facilitate drug development and manufacturing MONTREAL, June 2nd, 2021 – CQDM is proud to announce a partnership with 3 major pharmaceutical companies, Amgen Canada, Merck Canada, Servier Canada and the Canadian Glycomics Network (GlycoNet) as part of a $1,251,900 funding project. … Read More
Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI
Accélérer le passage de l’idée au marché – Dépôt du mémoire des RSRI dans le cadre des consultations publiques sur la Stratégie québécoise de la recherche et de l’innovation 2022. (Québec, le 31 mai 2021) – Les regroupements sectoriels de recherche industrielle (RSRI) ont déposé leurs propositions pour stimuler l’innovation dans le cadre des consultations publiques sur la Stratégie québécoise … Read More
- Page 1 of 2
- 1
- 2
